LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4 | -95.8% | 3,555 | -94.7% | 0.00% | – |
Q2 2023 | $95 | -90.5% | 67,600 | +7353.1% | 0.00% | – |
Q2 2022 | $1,000 | -99.1% | 907 | -98.7% | 0.00% | – |
Q1 2022 | $106,000 | -37.3% | 69,129 | +0.3% | 0.00% | – |
Q4 2021 | $169,000 | -2.9% | 68,922 | -0.3% | 0.00% | – |
Q3 2021 | $174,000 | -41.2% | 69,150 | -33.4% | 0.00% | – |
Q2 2021 | $296,000 | +410.3% | 103,900 | +49.5% | 0.00% | – |
Q1 2020 | $58,000 | -6.5% | 69,500 | 0.0% | 0.00% | – |
Q4 2019 | $62,000 | -8.8% | 69,500 | 0.0% | 0.00% | – |
Q3 2019 | $68,000 | – | 69,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |